Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Empagliflozin/Metformin 12.5/1000 mg Tablets in Healthy Subjects
NCT07633041Completed
- Sponsor
- Adium Pharma
- Start
- Feb 2025
- Primary completion
- Apr 2025
- Countries
- 1
01
Overview
Randomised, open-label trial of empagliflozin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Adium Pharma. Primary endpoints: Maximum Observed Plasma Concentration at 48 hours and Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration at 48 hours. Started Feb 2025; status: completed.
02
Drugs
empagliflozinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07633041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07633041.